# Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System

**Authors:** Jessica D. Austin, Ilyse A. Nelson, Jon C. Tilburt, Eric R. Ellinghysen, Claire Yee, Jaxon Quillen, Brian M. Dougan, John R. Presutti, Ryan T. Hurt, Niloy Jewel Samadder, Karthik Ghosh, Steven W. Ressler

PMC · DOI: 10.3390/jpm15100452 · Journal of Personalized Medicine · 2025-09-28

## TL;DR

Primary care clinicians are generally interested in multi-cancer detection tests but lack knowledge and have concerns about cost and misuse.

## Contribution

This study identifies gaps in clinician knowledge and preferences for learning about multi-cancer detection testing.

## Key findings

- Most clinicians expressed interest in MCD testing, but had limited knowledge and confidence.
- Cost and misuse were major concerns among clinicians.
- Online courses and classroom instruction were preferred methods for learning about MCD testing.

## Abstract

Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.

## Full-text entities

- **Diseases:** Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12565203/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12565203/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12565203/full.md

---
Source: https://tomesphere.com/paper/PMC12565203